The global anti-money laundering (AML) tools market is experiencing rapid growth, driven by increasing governmental focus on combating money laundering and terrorism financing, coupled with a surge in ...

The Government of Liberia has taken a decisive step toward implementing its multiuser rail policy by formally requesting that ...

Rydapt was approved by the FDA for first-line use in combination with induction and consolidation therapy in newly-diagnosed FLT3-positive AML patients in 2017, while Xospata was cleared a year ...

How can AI shift AML from detection to prevention? FinTechTalk explores the future of financial crime prevention.

Q4 2024 Management View Walter Klemp, Chairman and CEO, announced significant progress on the MIRACLE Phase 3 pivotal trial for Annamycin, targeting second-line treatment of relapsed and refractory ...

The return of Donald Trump to the White House signals dramatic shifts in sanctions policy and anti-money laundering ...

As Vidaza is a standard first-line therapy for AML the new indication makes Tibsovo an option for a wider range of patients, although the drug has reportedly been used off-label in this setting.